Hyperhomocysteinaemia, MTHFR or MTRR polymorphism and vitamin supplementation in Czech patients suffering from cardiovascular diseases

J. Hyánek; R. Matalon; P. Rady; S. Szucs; P. Šebesta; J. Matoušková; H. Pejznochová; L. Dubská; H. Přindisová; J. Dvořáková; M. Loučka; V. Martiníková; M. Slancová

Hyperhomocysteinaemia, MTHFR or MTRR polymorphism and vitamin supplementation in Czech patients suffering from cardiovascular diseases

J. Hyánek, R. Matalon, P. Rady, S. Szucs, P. Šebesta, J. Matoušková, H. Pejznochová, L. Dubská, H. Přindisová, J. Dvořáková, M. Loučka, V. Martiníková, M. Slancová

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

In a representative set of 27 Czech patients suffering from cardiovascular disease with mild hyperhomocysteinaemia (mHHC) (> 20μmol/l), polymorphisms of MTHFR 677 C > T, MTHFR 1289 and MTRR-Met were followed. The above mentioned patients were selected from a large group of patients (n=5884) according to intensity of their clinical and metabolic status. A significantly high incidence of MTHFR 677 C > T polymorphism was observed (p < 0,001). The incidence of other types of polymorphism (MTHFR 1289 and MTRR-Met) was not significantly changed. All hyperhomocysteinaemic patients were supplemented with critical vitamins (i.e. folate, cobalamin and pyridoxine). In 70% of patients with mHHC were folate reversible, 9 % cobalamin-reversible and 6% pyridoxal phosphate-reversible. 15% of patients-resistant to any supplementation of vitamins are now treated with hetaine or riboflavin.

Original language	English (US)
Pages (from-to)	72-76
Number of pages	5
Journal	Klinicka Biochemie a Metabolismus
Volume	10
Issue number	2
State	Published - 2002
Externally published	Yes

Keywords

Cobalamin
Folate
Mild hyperhomocysteinaemia vitamin supplementation
Polymorphism of MTHFR and MTRR
Pyridoxal phosphate

ASJC Scopus subject areas

Endocrinology, Diabetes and Metabolism
Endocrinology
Clinical Biochemistry

Cite this

Hyánek, J., Matalon, R., Rady, P., Szucs, S., Šebesta, P., Matoušková, J., Pejznochová, H., Dubská, L., Přindisová, H., Dvořáková, J., Loučka, M., Martiníková, V., & Slancová, M. (2002). Hyperhomocysteinaemia, MTHFR or MTRR polymorphism and vitamin supplementation in Czech patients suffering from cardiovascular diseases. Klinicka Biochemie a Metabolismus, 10(2), 72-76.

Hyánek, J, Matalon, R, Rady, P, Szucs, S, Šebesta, P, Matoušková, J, Pejznochová, H, Dubská, L, Přindisová, H, Dvořáková, J, Loučka, M, Martiníková, V & Slancová, M 2002, 'Hyperhomocysteinaemia, MTHFR or MTRR polymorphism and vitamin supplementation in Czech patients suffering from cardiovascular diseases', Klinicka Biochemie a Metabolismus, vol. 10, no. 2, pp. 72-76.

@article{4a369711e6454d1d9796f5b22a15feba,

title = "Hyperhomocysteinaemia, MTHFR or MTRR polymorphism and vitamin supplementation in Czech patients suffering from cardiovascular diseases",

abstract = "In a representative set of 27 Czech patients suffering from cardiovascular disease with mild hyperhomocysteinaemia (mHHC) (> 20μmol/l), polymorphisms of MTHFR 677 C > T, MTHFR 1289 and MTRR-Met were followed. The above mentioned patients were selected from a large group of patients (n=5884) according to intensity of their clinical and metabolic status. A significantly high incidence of MTHFR 677 C > T polymorphism was observed (p < 0,001). The incidence of other types of polymorphism (MTHFR 1289 and MTRR-Met) was not significantly changed. All hyperhomocysteinaemic patients were supplemented with critical vitamins (i.e. folate, cobalamin and pyridoxine). In 70% of patients with mHHC were folate reversible, 9 % cobalamin-reversible and 6% pyridoxal phosphate-reversible. 15% of patients-resistant to any supplementation of vitamins are now treated with hetaine or riboflavin.",

keywords = "Cobalamin, Folate, Mild hyperhomocysteinaemia vitamin supplementation, Polymorphism of MTHFR and MTRR, Pyridoxal phosphate",

author = "J. Hy{\'a}nek and R. Matalon and P. Rady and S. Szucs and P. {\v S}ebesta and J. Matou{\v s}kov{\'a} and H. Pejznochov{\'a} and L. Dubsk{\'a} and H. P{\v r}indisov{\'a} and J. Dvo{\v r}{\'a}kov{\'a} and M. Lou{\v c}ka and V. Martin{\'i}kov{\'a} and M. Slancov{\'a}",

year = "2002",

language = "English (US)",

volume = "10",

pages = "72--76",

journal = "Klinicka Biochemie a Metabolismus",

issn = "1210-7921",

publisher = "Czech Medical Association J.E. Purkyne",

number = "2",

}

TY - JOUR

T1 - Hyperhomocysteinaemia, MTHFR or MTRR polymorphism and vitamin supplementation in Czech patients suffering from cardiovascular diseases

AU - Hyánek, J.

AU - Matalon, R.

AU - Rady, P.

AU - Szucs, S.

AU - Šebesta, P.

AU - Matoušková, J.

AU - Pejznochová, H.

AU - Dubská, L.

AU - Přindisová, H.

AU - Dvořáková, J.

AU - Loučka, M.

AU - Martiníková, V.

AU - Slancová, M.

PY - 2002

Y1 - 2002

N2 - In a representative set of 27 Czech patients suffering from cardiovascular disease with mild hyperhomocysteinaemia (mHHC) (> 20μmol/l), polymorphisms of MTHFR 677 C > T, MTHFR 1289 and MTRR-Met were followed. The above mentioned patients were selected from a large group of patients (n=5884) according to intensity of their clinical and metabolic status. A significantly high incidence of MTHFR 677 C > T polymorphism was observed (p < 0,001). The incidence of other types of polymorphism (MTHFR 1289 and MTRR-Met) was not significantly changed. All hyperhomocysteinaemic patients were supplemented with critical vitamins (i.e. folate, cobalamin and pyridoxine). In 70% of patients with mHHC were folate reversible, 9 % cobalamin-reversible and 6% pyridoxal phosphate-reversible. 15% of patients-resistant to any supplementation of vitamins are now treated with hetaine or riboflavin.

AB - In a representative set of 27 Czech patients suffering from cardiovascular disease with mild hyperhomocysteinaemia (mHHC) (> 20μmol/l), polymorphisms of MTHFR 677 C > T, MTHFR 1289 and MTRR-Met were followed. The above mentioned patients were selected from a large group of patients (n=5884) according to intensity of their clinical and metabolic status. A significantly high incidence of MTHFR 677 C > T polymorphism was observed (p < 0,001). The incidence of other types of polymorphism (MTHFR 1289 and MTRR-Met) was not significantly changed. All hyperhomocysteinaemic patients were supplemented with critical vitamins (i.e. folate, cobalamin and pyridoxine). In 70% of patients with mHHC were folate reversible, 9 % cobalamin-reversible and 6% pyridoxal phosphate-reversible. 15% of patients-resistant to any supplementation of vitamins are now treated with hetaine or riboflavin.

KW - Cobalamin

KW - Folate

KW - Mild hyperhomocysteinaemia vitamin supplementation

KW - Polymorphism of MTHFR and MTRR

KW - Pyridoxal phosphate

UR - http://www.scopus.com/inward/record.url?scp=18344367818&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18344367818&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:18344367818

SN - 1210-7921

VL - 10

SP - 72

EP - 76

JO - Klinicka Biochemie a Metabolismus

JF - Klinicka Biochemie a Metabolismus

IS - 2

ER -

Hyperhomocysteinaemia, MTHFR or MTRR polymorphism and vitamin supplementation in Czech patients suffering from cardiovascular diseases

Abstract

Keywords

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this